These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 33626496)

  • 1. Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer.
    Lozano R; Salles DC; Sandhu S; Aragón IM; Thorne H; López-Campos F; Rubio-Briones J; Gutierrez-Pecharroman AM; Maldonado L; di Domenico T; Sanz A; Prieto JD; García I; Pacheco MI; Garcés T; Llacer C; Romero-Laorden N; Zambrana F; López-Casas PP; Lorente D; Mateo J; Pritchard CC; Antonarakis ES; Olmos D; Lotan TL; Castro E
    Eur J Cancer; 2021 Apr; 147():74-83. PubMed ID: 33626496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers.
    Lozano R; Castro E; Lopez-Campos F; Thorne H; Ramirez-Backhaus M; Aragon IM; Cendón-Florez Y; Gutierrez-Pecharroman A; Salles DC; Romero-Laorden N; Lorente D; González-Peramato P; Calatrava A; Alonso C; Anido U; Arévalo-Lobera S; Balmaña J; Chirivella I; Juan-Fita MJ; Llort G; Y Cajal TR; Almagro E; Alameda D; López-Casas PP; Herrera B; Mateo J; Pritchard CC; Antonarakis ES; Lotan TL; Rubio-Briones J; Sandhu S; Olmos D
    Eur J Cancer; 2023 May; 185():105-118. PubMed ID: 36972661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-derived xenografts reveal that intraductal carcinoma of the prostate is a prominent pathology in BRCA2 mutation carriers with prostate cancer and correlates with poor prognosis.
    Risbridger GP; Taylor RA; Clouston D; Sliwinski A; Thorne H; Hunter S; Li J; Mitchell G; Murphy D; Frydenberg M; Pook D; Pedersen J; Toivanen R; Wang H; Papargiris M; Lawrence MG; Bolton DM
    Eur Urol; 2015 Mar; 67(3):496-503. PubMed ID: 25154392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations.
    Khani F; Wobker SE; Hicks JL; Robinson BD; Barbieri CE; De Marzo AM; Epstein JI; Pritchard CC; Lotan TL
    J Pathol; 2019 Sep; 249(1):79-89. PubMed ID: 30993692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of MYC/PTEN Status by Gene-Protein Assay in Grade Group 2 Prostate Biopsies.
    Salles DC; Vidotto T; Faisal FA; Tosoian JJ; Guedes LB; Muranyi A; Bai I; Singh S; Yan D; Shanmugam K; Lotan TL
    J Mol Diagn; 2021 Aug; 23(8):1030-1041. PubMed ID: 34062284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTEN loss in prostatic adenocarcinoma correlates with specific adverse histologic features (intraductal carcinoma, cribriform Gleason pattern 4 and stromogenic carcinoma).
    Shah RB; Shore KT; Yoon J; Mendrinos S; McKenney JK; Tian W
    Prostate; 2019 Aug; 79(11):1267-1273. PubMed ID: 31111513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between pathogenic germline mutations in BRCA2 and ATM and tumor-infiltrating lymphocytes in primary prostate cancer.
    Kaur HB; Vidotto T; Mendes AA; Salles DC; Isaacs WB; Antonarakis ES; Lotan TL
    Cancer Immunol Immunother; 2022 Apr; 71(4):943-951. PubMed ID: 34533610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cribriform and intraductal prostate cancer are associated with increased genomic instability and distinct genomic alterations.
    Böttcher R; Kweldam CF; Livingstone J; Lalonde E; Yamaguchi TN; Huang V; Yousif F; Fraser M; Bristow RG; van der Kwast T; Boutros PC; Jenster G; van Leenders GJLH
    BMC Cancer; 2018 Jan; 18(1):8. PubMed ID: 29295717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated analysis of the genomic instability of PTEN in clinically insignificant and significant prostate cancer.
    Murphy SJ; Karnes RJ; Kosari F; Castellar BE; Kipp BR; Johnson SH; Terra S; Harris FR; Halling GC; Klein JL; Nasir A; Bergstrahl E; Rangel LJ; Sukov WR; Vasmatzis G; Cheville JC
    Mod Pathol; 2016 Feb; 29(2):143-56. PubMed ID: 26612463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cribriform Prostate Cancer: Clinical Pathologic and Molecular Considerations.
    Hesterberg AB; Gordetsky JB; Hurley PJ
    Urology; 2021 Sep; 155():47-54. PubMed ID: 34058243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical Intraductal Cribriform Proliferations of the Prostate Exhibit Similar Molecular and Clinicopathologic Characteristics as Intraductal Carcinoma of the Prostate.
    Hickman RA; Yu H; Li J; Kong M; Shah RB; Zhou M; Melamed J; Deng FM
    Am J Surg Pathol; 2017 Apr; 41(4):550-556. PubMed ID: 28009609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories.
    Taylor RA; Fraser M; Livingstone J; Espiritu SM; Thorne H; Huang V; Lo W; Shiah YJ; Yamaguchi TN; Sliwinski A; Horsburgh S; Meng A; Heisler LE; Yu N; Yousif F; Papargiris M; Lawrence MG; Timms L; Murphy DG; Frydenberg M; Hopkins JF; Bolton D; Clouston D; McPherson JD; van der Kwast T; Boutros PC; Risbridger GP; Bristow RG
    Nat Commun; 2017 Jan; 8():13671. PubMed ID: 28067867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTEN loss and p27 loss differ among morphologic patterns of prostate cancer, including cribriform.
    Ronen S; Abbott DW; Kravtsov O; Abdelkader A; Xu Y; Banerjee A; Iczkowski KA
    Hum Pathol; 2017 Jul; 65():85-91. PubMed ID: 28504208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prostate cancer with BRCA2 pathogenic mutation: a clinicopathological analysis].
    Wang DH; Yin WL; Pan XY; Zhang MN; Nie L; Chen XQ; Zeng H; Zhou Q; Chen N
    Zhonghua Bing Li Xue Za Zhi; 2024 Aug; 53(8):789-796. PubMed ID: 39103259
    [No Abstract]   [Full Text] [Related]  

  • 15. A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies.
    Chua MLK; Lo W; Pintilie M; Murgic J; Lalonde E; Bhandari V; Mahamud O; Gopalan A; Kweldam CF; van Leenders GJLH; Verhoef EI; Hoogland AM; Livingstone J; Berlin A; Dal Pra A; Meng A; Zhang J; Orain M; Picard V; Hovington H; Bergeron A; Lacombe L; Fradet Y; Têtu B; Reuter VE; Fleshner N; Fraser M; Boutros PC; van der Kwast TH; Bristow RG
    Eur Urol; 2017 Nov; 72(5):665-674. PubMed ID: 28511883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic Features and Clinical Implications of Intraductal Carcinoma of the Prostate.
    Kang M; Lee H; Byeon SJ; Kwon GY; Jeon SS
    Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between cribriform/intraductal prostatic adenocarcinoma and percent Gleason pattern 4 to a 22-gene genomic classifier.
    Taylor AS; Morgan TM; Wallington DG; Chinnaiyan AM; Spratt DE; Mehra R
    Prostate; 2020 Feb; 80(2):146-152. PubMed ID: 31737920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate.
    Zhao J; Sun G; Zhu S; Dai J; Chen J; Zhang M; Ni Y; Zhang H; Shen P; Zhao X; Zhang B; Pan X; Nie L; Yin X; Liang J; Zhang X; Wang Z; Zhu X; Liao B; Liu Z; Armstrong CM; Gao AC; Huang H; Chen N; Zeng H
    BJU Int; 2022 Mar; 129(3):345-355. PubMed ID: 34185954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High burden of copy number alterations and c-MYC amplification in prostate cancer from BRCA2 germline mutation carriers.
    Castro E; Jugurnauth-Little S; Karlsson Q; Al-Shahrour F; Piñeiro-Yañez E; Van de Poll F; Leongamornlert D; Dadaev T; Govindasami K; Guy M; Eeles R; Kote-Jarai Z;
    Ann Oncol; 2015 Nov; 26(11):2293-300. PubMed ID: 26347108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland.
    Wokołorczyk D; Kluźniak W; Huzarski T; Gronwald J; Szymiczek A; Rusak B; Stempa K; Gliniewicz K; Kashyap A; Morawska S; Dębniak T; Jakubowska A; Szwiec M; Domagała P; Lubiński J; Narod SA; Akbari MR; Cybulski C;
    Int J Cancer; 2020 Nov; 147(10):2793-2800. PubMed ID: 32875559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.